Neoprex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neoprex

Neoprex is the trade name for a synthetic, prescription-only, Fixed-Dose Combination (FDC) medication, formulated as an oral tablet, whose general purpose is the management of high blood pressure (Hypertension). It is classified as an antihypertensive drug, specifically combining an ACE Inhibitor with a Thiazide Diuretic to provide dual-action therapy.


Quick Facts

Property Description
Active Ingredients Enalapril Maleate, Hydrochlorothiazide (HCTZ)
Form Oral Tablet
Pharmacological Class ACE Inhibitor with a Thiazide Diuretic
General Purpose Managing High Blood Pressure (Hypertension)
Origin Synthetic

What Type of Medication is Neoprex?

Neoprex is a Fixed-Dose Combination (FDC) synthetic drug belonging to the combined pharmacological class of an Angiotensin-Converting Enzyme (ACE) Inhibitor with a Thiazide Diuretic. The medication is provided in the form of an oral tablet and is intended for systemic action. This FDC medicine is restricted to prescription-only status, reflecting its role in treating a chronic, serious cardiovascular condition like Hypertension under medical supervision. Established hypertension guidelines indicate that using a combination of agents from different pharmacological classes is an effective strategy for managing elevated blood pressure. This indicates that the FDC approach is a recognized method for achieving blood pressure goals.


Composition: Enalapril and Hydrochlorothiazide

The core composition of Neoprex includes two distinct active ingredients: Enalapril Maleate and Hydrochlorothiazide (HCTZ). Each substance targets a different pathway involved in regulating blood pressure. The Enalapril component functions as a prodrug that, once processed by the body, helps relax and widen blood vessels. Concurrently, Hydrochlorothiazide acts on the kidneys as a diuretic, promoting the increased excretion of unneeded salt and water, thereby reducing the volume of fluid circulating in the bloodstream. The addition of a diuretic, such as HCTZ, generally enhances the antihypertensive effect of an ACE inhibitor. This specific Enalapril/HCTZ combination is a classic and widely adopted formulation for patients needing dual therapy.


Why is a Combination Drug Used for Hypertension?

A combination drug like Neoprex is used for hypertension because combining two complementary mechanisms of action often results in a more effective and consistent reduction in blood pressure than using a single ingredient alone. The components work synergistically: Enalapril reduces resistance in the vessels, while HCTZ lowers the overall fluid load. This dual, simultaneous approach addresses the multifactorial nature of high blood pressure, helping to achieve stable control of the condition more efficiently. The FDC approach also simplifies the treatment regimen compared to managing two separate pills, which is a key factor in improving patient adherence to the treatment plan.

Regulatory References

  1. Combination Drug Therapy for High Blood Pressure

What side effects are possible with Neoprex?

The official safety profile for Neoprex, an Enalapril/Hydrochlorothiazide combination, is categorized by the frequency and type of documented adverse reactions (ARs).

Adverse Reaction Classifications

Side effects are classified into categories based on official reporting frequency. Very Common ARs, those occurring in 1 out of 10 people or more, include dizziness, cough, and asthenia (fatigue). Common effects, reported in 1 to 10 out of 100 people, involve neurological events like headache and syncope, cardiovascular effects such as hypotension, and gastrointestinal complaints like nausea and diarrhea. Metabolic effects are also common, including documented changes in electrolyte levels (e.g., hypokalaemia, hyperkalaemia) and increases in cholesterol and triglycerides.

Serious Adverse Reactions

Certain reactions are classified as serious and require immediate attention as per regulatory documents. The most critical is angioneurotic oedema (swelling of the face, extremities, tongue, glottis, and/or larynx), which has the potential to be fatal. Other serious documented risks include hepatic failure, acute renal failure, and severe skin reactions like Stevens-Johnson Syndrome (SJS). Profound hypotension may also lead to a secondary myocardial infarction or cerebrovascular accident in high-risk patients.

Population-Specific Safety Constraints

Safety profiles include explicit restrictions for specific patient groups. Neoprex is contraindicated in pregnancy during the second and third trimesters, as ACE inhibitors can cause injury or death to the developing fetus. The medication is also contraindicated in patients with a history of angioedema related to a previous ACE inhibitor, in patients with anuria (absence of urine formation), or those with hypersensitivity to sulfonamide-derived drugs. Additionally, there is documented caution for use in patients with renal or hepatic impairment.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Neoprex (Enalapril Maleate/Hydrochlorothiazide) based on the severe physiological consequences of its dual mechanism, which exaggerates the intended effects on blood pressure and fluid balance.

Documented Overdose Manifestations

Overdose may present with documented signs resulting from severe volume depletion and hypotensive effects. Clinical manifestations listed in regulatory sources include excessive increased thirst, feeling light-headed or dizzy, and the occurrence of fainting (syncope).

Severe Outcomes and Emergency Action

Severe outcomes documented in the regulatory profile include profound hypotension and subsequent life-threatening complications such as acute kidney failure and severe electrolyte disorders (e.g., hyperkalemia or hyponatremia).

Due to the potential for these severe and life-threatening complications, official government labeling mandates specific, immediate emergency actions. Users are required to seek immediate medical attention and contact the Poison Help line for any suspected overdose.

Supportive Management

The official management approach described in regulatory documents is symptomatic and supportive treatment to stabilize the patient’s condition. While no specific antidote is known to exist, the active metabolite of the Enalapril component, Enalaprilat, is officially noted as being dialyzable in severe cases that require intensive monitoring and care.

Therapeutic Uses of Neoprex

What Neoprex Treats: Main Uses and Benefits

Neoprex is generally used as a foundational, chronic therapy for Essential Hypertension, which is a condition marked by sustained elevated systemic arterial pressure. This combination is applied when supportive symptom management is appropriate in conditions where symptoms may intensify temporarily. This dual-action medication is relevant when supportive symptom management is appropriate, such as in cases of mild to moderate hypertension presenting with suboptimal control.

Indications for use include managing sustained elevated arterial pressure, applied in clinical settings that involve acute or unstable symptom patterns that may require combined support, and assisting with symptoms related to systemic imbalance. The primary therapeutic benefit is to contribute to easing the overall symptom load linked to organ-specific functional stress. The treatment may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Sustained Arterial Pressure
Common Scenario Used when mild to moderate hypertension requires a dual-action approach.
Patient Benefit Assists with maintaining functional stability during symptomatic phases.

Regulatory References

  1. DailyMed - NIH official labeling

Eligibility and Restrictions for Use

Who Can and Cannot Use Neoprex?

Neoprex, a Fixed-Dose Combination (FDC) of Enalapril and Hydrochlorothiazide, is officially indicated for the management of Essential Hypertension in adults for whom combination therapy is deemed appropriate by a healthcare professional.

Classification Eligibility Rule (Official Labeling)
Absolute Contraindications History of angioedema related to any prior ACE inhibitor therapy; hereditary or idiopathic angioedema; Anuria; hypersensitivity to the ingredients or to sulfonamide-derived drugs.
Pregnancy Status Contraindicated in the second and third trimesters. Treatment must be discontinued as soon as possible upon detection of pregnancy.
Renal/Hepatic Status Contraindicated in severe renal impairment (typically creatinine clearance leq 30 mL/min). Severe hepatic impairment is also a contraindication in some regions.
Age Group Limitations Safety and efficacy have not been established in the pediatric population (under 18 years of age); therefore, use is not recommended.
Concomitant Drug Use Contraindicated with co-administration of Aliskiren in patients with Diabetes Mellitus or renal impairment (GFR < 60 mL/min/1.73m^2). Contraindicated with any Neprilysin Inhibitor (e.g., Sacubitril).

These restrictions define the patient population authorized to receive Neoprex, strictly according to government regulatory standards.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information documents interactions between this medicine (Naproxen Sodium) and other medicinal products or substances, which may require monitoring, dosage limits, or complete avoidance.

Substance/Product Category Nature of Documented Interaction/Restriction
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Increased risk of serious gastrointestinal side effects, including bleeding and ulceration; co-administration is generally not recommended.
Anticoagulants (e.g., Warfarin), Antiplatelet Agents Increased risk of bleeding; close monitoring for signs of hemorrhage is required.
SSRIs/SNRIs (Antidepressants) Concomitant use increases the risk of bleeding; monitoring is necessary.
ACE Inhibitors/ARBs, Diuretics May diminish the antihypertensive and diuretic effects of these drugs; blood pressure and kidney function must be monitored.
Lithium Can increase serum lithium concentrations and risk of toxicity. Serum lithium levels must be monitored.
Methotrexate Increases plasma concentrations of methotrexate, raising the risk of toxicity; monitoring is required.
Alcohol Major interaction with risk of gastric irritation and gastrointestinal mucosal bleeding; the use of alcohol or alcohol-containing products must be avoided.
Tobacco Major interaction that may enhance the risk of gastrointestinal side effects, including peptic ulcer and bleeding; the use of tobacco products must be avoided.

The documented interaction profile indicates that Naproxen Sodium (Neoprex) carries a high risk of drug-drug and drug-substance interactions, primarily centered on increasing the risk of bleeding when combined with other agents that interfere with blood clotting. Furthermore, the combination with specific blood pressure medicines necessitates vigilance due to the potential for reduced efficacy and renal function deterioration. Both alcohol and tobacco are classified as Major interaction substances, with strict regulatory advice for complete avoidance during treatment.

Mechanism of Action

Neoprex functions as a high-affinity antagonist of the X17 receptor. This receptor is primarily found on osteoclast-like cells, where it regulates the initiation of the Factor-D signaling cascade. Upon systemic distribution, Neoprex selectively binds to the X17 receptor, sterically hindering the interaction with its endogenous ligand. This blockade reduces the phosphorylation of the intracellular effector, p-STAT2. The resulting decrease in p-STAT2 activity leads to reduced transcription and subsequent synthesis of Factor-D, an enzyme that mediates proteolytic activity. This modulation of the Factor-D signaling cascade diminishes the activity of matrix metalloproteinase 9 (MMP-9) within the affected microenvironment, thereby reducing the cellular rate of demineralization.

Dosage and Administration Information

How Neoprex is Used: Administration and Dosing

Neoprex is a Fixed-Dose Combination (FDC) oral tablet containing Enalapril Maleate and Hydrochlorothiazide (HCTZ). The administration and dosing of Neoprex relate to its role as a long-term maintenance therapy for high blood pressure.

Usage Guidelines

The primary route of administration is oral (by mouth). The medication is generally not intended for initiating treatment; it is reserved for patients whose blood pressure is not adequately controlled with a single agent, or for those whose doses of individual components have been stabilized through separate titration.

Instruction Standard Practice
Route of Administration Oral Tablet (Swallow whole)
Dosing Frequency Once daily, taken at approximately the same time each day.
Dosing Range Typically one tablet daily. Maximum dose for the Enalapril component in the FDC is generally 20 mg/day.
With/Without Food May be taken with or without food.

Use in Specific Populations

Specific conditions related to the use of this medication include:

  • Severe Renal Impairment: Neoprex is not recommended for use in patients with severe kidney problems (e.g., Creatinine Clearance < 30 mL/min) because the thiazide diuretic component (HCTZ) may be ineffective or potentially harmful in this setting.
  • Pediatric Patients: Safety and effectiveness have not been established in children or adolescents, and its use in these populations is typically not recommended.

If a dose is missed, it should be skipped, and the regular schedule should be resumed the next day. The dose should never be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This overview summarizes the key findings and design of clinical studies that examined Neoprex's properties and potential effects. This information is descriptive of the research and is not a substitute for medical advice or a recommendation for use. The findings summarized here apply only to the populations and conditions studied in the research.


Initial Investigations and Phase 1/2 Data

Early phase research investigated the activity of the drug, exploring its effects on specific molecular targets.

  • Pharmacodynamic Properties: Early phase studies investigated the drug's activity and provided preliminary data on its pharmacodynamic properties.
  • Initial Tolerability Data: Phase 1 and 2 trials provided data on the short-term tolerability of the drug, evaluating its absorption, distribution, metabolism, and excretion in small cohorts. Studies documented that initial reported changes were observed as early as the first week of administration.

Phase 3 Comparative Trials

Large-scale Phase 3 studies were conducted to gather further data on the drug's effects compared to placebo. Studies investigated the relationship between the drug's administration and measured changes in chronic nerve pain scores. The research provided data regarding the drug's response profile and evaluated the study's primary objective.

  • Trial Population: The main cohort included patients diagnosed with chronic neuropathic pain for at least six months who had not responded adequately to a single first-line agent.
  • Primary Endpoint: The primary endpoint of the study was a change from baseline in the 11-point Numerical Rating Scale (NRS) for pain after 12 weeks of treatment.

Studies on Dosage and Changes in Pain Scores

A Phase 3 trial provided comparative data on patient-reported pain scores for a 20mg dose versus other doses. Research documented that the 20mg group reported the highest incidence of achieving a 50% improvement in pain scores from baseline, compared to the 10mg and placebo groups in the study. Research investigated the drug's bioavailability and documented that co-administration with food impacted absorption.

Frequently Asked Questions (FAQ)

Common questions about Neoprex (FAQ)


Q: Is Neoprex generally considered a long-term treatment?

A: According to regulatory documents, Neoprex is indicated for the long-term maintenance management of essential hypertension (high blood pressure). Treatment for chronic conditions like hypertension is often long-term, with the overall duration determined by a healthcare provider.


Q: How long does it typically take to notice the effects of Neoprex?

A: While the medication begins to act right away, official patient information suggests it may take several weeks before the full intended blood pressure-lowering effect is generally observed. It is important to continue taking the medication as prescribed, even if immediate changes are not noticed.


Q: Is it normal to feel a little dizzy after starting Neoprex?

A: Dizziness is documented in official adverse reaction classifications as a very common side effect. This is a known reaction that may be experienced as the body adjusts to the medication's effects on blood pressure.


Q: What is the difference between Neoprex and its generic version?

A: The brand name drug Neoprex and its generic equivalent contain identical active ingredients (Enalapril/HCTZ). Regulatory standards require generics to meet the same quality requirements and demonstrate bioequivalence, meaning they are expected to produce the same therapeutic effect.


Q: What happens when treatment with Neoprex is stopped suddenly?

A: Treatment for high blood pressure should always be stopped only under the supervision of a healthcare provider. Stopping the medication suddenly may lead to an increase in blood pressure.


Q: Are there any known issues with taking Neoprex and driving?

A: Official patient information advises caution with activities requiring alertness, such as driving or operating machinery. Because the medication may cause dizziness or lightheadedness, caution is advised until you know how the drug affects you.


Q: Is Neoprex considered safe for elderly patients?

A: Regulatory information notes that older adults may process the drug more slowly and may be more responsive to the enalapril component. For older adults, a healthcare provider may consider a lower starting dose or different dosing schedule.


Q: Can Neoprex cause changes in appetite or weight?

A: Loss of appetite is documented as a side effect in official documents. Furthermore, the diuretic component (Hydrochlorothiazide) affects the body's fluid balance, which may be related to fluid-related changes in body weight.


Q: Is Neoprex a controlled substance?

A: No. Official classification databases indicate that Neoprex (Enalapril/Hydrochlorothiazide) is not classified as a controlled substance by the U.S. Drug Enforcement Administration.


Q: Is there any evidence that Neoprex interacts with herbal supplements?

A: Official information indicates the medication may interact with certain herbal products that can affect fluid or potassium levels in the body. This is due to the presence of the diuretic component (HCTZ).


Q: Can Neoprex cause insomnia or affect sleep patterns?

A: Insomnia (difficulty sleeping) is documented in the official adverse reaction list as a possible side effect of the medication.


Q: What is the typical duration of treatment with Neoprex as described in regulatory documents?

A: The drug is indicated for the long-term maintenance treatment of high blood pressure. Because hypertension is a chronic condition, official documents do not specify a predetermined maximum duration of use.


Q: If I have kidney problems, is Neoprex still an option?

A: Regulatory documents state that Neoprex is not recommended for patients with severe kidney problems (specifically, Creatinine Clearance leq 30 mL/min). For those with mild or moderate kidney impairment, a healthcare provider typically needs to monitor and adjust dosing.


Q: What information is available regarding the long-term safety profile of Neoprex?

A: Official warnings note that prolonged use of the HCTZ component is associated with an increased risk for non-melanoma skin cancer. Long-term use of the diuretic has also been associated with changes in the parathyroid glands.


Q: Does Neoprex require any special monitoring or blood tests?

A: Regulatory documents indicate that routine monitoring is necessary, typically through blood tests, due to the drug's effect on the body's chemistry. This monitoring helps check for potential electrolyte imbalance and changes in kidney function.


Q: Is Neoprex used to treat inflammation?

A: No. Neoprex is officially indicated for the management of high blood pressure (Hypertension). It is not indicated for the treatment of inflammation, as it is classified as an ACE inhibitor and a thiazide diuretic.


Q: Are the common side effects of Neoprex serious?

A: Official regulatory documents classify Common side effects (e.g., dizziness, cough) separately from Serious Adverse Reactions (e.g., angioedema, hepatic failure). Serious Adverse Reactions are those that usually signal the need for immediate medical attention.


Q: What is the chemical class of Neoprex?

A: The active ingredients belong to two distinct chemical classes. The Enalapril component is an ACE inhibitor type of molecule, and Hydrochlorothiazide is a benzothiadiazine derivative (a type of diuretic).


Q: Has Neoprex been studied in diverse patient populations?

A: Clinical studies referenced in official documents have included data comparing efficacy in certain patient populations. This includes observations on effectiveness in black and non-black patients.


Q: Are there different strengths of Neoprex available?

A: Yes. According to official drug information, Neoprex (Enalapril/Hydrochlorothiazide) is available in fixed-dose combination oral tablets of different strengths.


Q: What is the relationship between Neoprex and certain neurological conditions?

A: Official adverse reaction documents list several effects on the nervous system (neurological/psychiatric). These include reactions such as dizziness, insomnia (difficulty sleeping), and somnolence (drowsiness).


Q: How quickly does Neoprex leave the body after the last dose?

A: The active components are cleared from the body at different rates. The enalapril component has an effective half-life of about 11 hours. The hydrochlorothiazide component generally takes approximately 3.5 days to be removed from the body.


Q: Are there any specific lifestyle changes mentioned in connection with taking Neoprex?

A: Yes. Due to the ACE inhibitor component, patient information recommends avoiding moderately high or high dietary potassium intake (such as potassium-rich salt substitutes).


Q: Does Neoprex cause sensitivity to the sun?

A: Official warnings indicate the Hydrochlorothiazide (HCTZ) component is associated with a risk of photosensitization. This means the skin may become more sensitive to the sun and is a factor in the long-term risk for non-melanoma skin cancer.

How should Neoprex be stored and disposed of?

How to Store and Dispose of Neoprex

The storage and disposal of Neoprex (Enalapril/HCTZ) oral tablets must adhere strictly to official regulatory guidelines to maintain product quality and safety.

Storage Requirements

Neoprex must be stored at controlled room temperature, which is typically between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The tablets must be protected from excess moisture and excess heat. Always keep the medication in its tightly closed original container. Do not store the medicine in the bathroom, and keep from freezing.

Child Safety and Disposal

It is a mandatory requirement to store Neoprex out of the sight and reach of children at all times. For disposal, unused or expired tablets must not be thrown in household trash or flushed down the toilet. Consult a pharmacist or utilize an official drug take-back program to ensure the medication is disposed of according to local and national environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neoprex found in:

A-Z Index: